Humes H David, Buffington Deborah, Westover Angela J, Roy Shuvo, Fissell William H
Innovative BioTherapies, Inc., 650 Avis Dr., Suite 300, Ann Arbor, MI, 48108, USA,
Pediatr Nephrol. 2014 Mar;29(3):343-51. doi: 10.1007/s00467-013-2467-y. Epub 2013 Apr 26.
The rapid understanding of the cellular and molecular bases of organ function and disease processes will be translated in the next decade into new therapeutic approaches to a wide range of clinical disorders, including acute and chronic renal failure. Central to these new therapies are the developing technologies of cell therapy and tissue engineering, which are based on the ability to expand stem or progenitor cells in tissue culture to perform differentiated tasks and to introduce these cells into the patient either via extracorporeal circuits or as implantable constructs. Cell therapy devices are currently being developed to replace the filtrative, metabolic, and endocrinologic functions of the kidney lost in both acute and chronic renal failure. This review summarizes the current state of development of a wearable or implantable bioartificial kidney. These devices have the promise to be combined to produce a wearable or implantable bioartificial kidney for full renal replacement therapy that may significantly diminish morbidity and mortality in patients with acute or chronic kidney disease.
在未来十年,对器官功能和疾病过程的细胞及分子基础的快速理解将转化为针对包括急性和慢性肾衰竭在内的多种临床疾病的新治疗方法。这些新疗法的核心是细胞治疗和组织工程等不断发展的技术,其基于在组织培养中扩增干细胞或祖细胞以执行分化任务并通过体外循环或作为可植入构建体将这些细胞引入患者体内的能力。目前正在开发细胞治疗设备,以替代急性和慢性肾衰竭中丧失的肾脏的过滤、代谢和内分泌功能。本综述总结了可穿戴或可植入生物人工肾的当前发展状况。这些设备有望结合起来,生产出用于全肾替代治疗的可穿戴或可植入生物人工肾,这可能会显著降低急性或慢性肾病患者的发病率和死亡率。